Binosto Related Published Studies
Well-designed clinical trials related to Binosto (Alendronate)
A randomized, double blind, placebo-controlled trial of alendronate treatment for
fibrous dysplasia of bone. [2014]
Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal
Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical
trial. [2013]
Comparing tolerability and efficacy of generic versus brand alendronate: a
randomized clinical study in postmenopausal women with a recent fracture. [2013]
Effects of adding alendronate to ongoing hormone therapy on bone mineral density
in postmenopausal Korean women: a randomized, double-blind, placebo-controlled
clinical trial. [2013]
Targeted anti-inflammatory systemic therapy for restenosis: the Biorest Liposomal
Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical
trial. [2013]
Alendronate and atrial fibrillation: a meta-analysis of randomized
placebo-controlled clinical trials. [2012]
Efficacy of continued alendronate for fractures in women with and without
prevalent vertebral fracture: the FLEX trial. [2010]
Bone formation markers in patients with glucocorticoid-induced osteoporosis
treated with teriparatide or alendronate. [2010]
Effects of denosumab on bone mineral density and bone turnover in postmenopausal
women transitioning from alendronate therapy. [2010]
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone
loss: a 12-month randomized, placebo-controlled clinical trial. [2009]
A double-blinded head-to-head trial of minodronate and alendronate in women with
postmenopausal osteoporosis. [2009]
Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin
D3 for osteoporosis: results from the 24-week extension of a 15-week randomized,
controlled trial. [2009]
Randomized, active-controlled study of once-weekly alendronate 280 mg high dose
oral buffered solution for treatment of Paget's disease. [2009]
Changes in bone markers after once-weekly low-dose alendronate in postmenopausal
women with moderate bone loss. [2008]
Treatment with alendronate plus calcium, alendronate alone, or calcium alone for
postmenopausal low bone mineral density. [2007]
Prevention of glucocorticoid induced osteoporosis with alendronate or
alfacalcidol: relations of change in bone mineral density, bone markers, and
calcium homeostasis. [2007]
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and
without alendronate for osteoporosis. [2007]
Effects of continuing or stopping alendronate after 5 years of treatment: the
Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. [2006]
Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone
metabolism in Korean postmenopausal women: a multicenter, double-blind,
randomized, placebo-controlled study. [2006]
Alendronate with and without cholecalciferol for osteoporosis: results of a
15-week randomized controlled trial. [2006]
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate
versus risedronate over two years. [2006]
Alendronate/colecalciferol. [2005]
Impact of alendronate on quality of life in children with osteogenesis
imperfecta. [2005]
A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral
solution for postmenopausal osteoporosis. [2005]
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. [2005]
Effect of hormone replacement, alendronate, or combination therapy on hip
structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. [2005]
Monitoring alendronate and estradiol therapy with quantitative ultrasound and
bone mineral density. [2005]
Differential effects of teriparatide and alendronate on bone remodeling in
postmenopausal women assessed by histomorphometric parameters. [2005]
Effect of alendronate on the age-specific incidence of symptomatic osteoporotic
fractures. [2005]
Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized,
double-blind, placebo-controlled trial. [2005]
Effect of alendronate on vertebral fracture risk in women with bone mineral
density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention
Trial. [2005]
Upper gastrointestinal tolerability of once weekly alendronate 70 mg with
concomitant non-steroidal anti-inflammatory drug use. [2005]
Early changes in biochemical markers of bone turnover are associated with
long-term changes in bone mineral density in elderly women on alendronate,
hormone replacement therapy, or combination therapy: a three-year, double-blind,
placebo-controlled, randomized clinical trial. [2005]
Well-designed clinical trials possibly related to Binosto (Alendronate)
Clinical Trials Express: fracture risk reduction with denosumab in Japanese
postmenopausal women and men with osteoporosis: denosumab fracture intervention
randomized placebo controlled trial (DIRECT). [2014]
Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal
osteoporosis by mixed treatment comparison meta-analysis. [2013]
[Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis]. [Article in Japanese] [2012]
Bone turnover markers and bone mineral density response with risedronate therapy:
relationship with fracture risk and patient adherence. [2011]
Antifracture efficacy of currently available therapies for postmenopausal
osteoporosis. [2011]
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. [2010]
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly
tablet for treatment of low bone mass. [2010]
Does a history of non-vertebral fracture identify women without osteoporosis for
treatment? [2008]
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of
postmenopausal women with low BMD. [2007]
[Randomized controlled trials for the prevention and treatment of
glucocorticoid-induced osteoporosis]. [Article in Japanese] [2006]
Response rate of bone mineral density to teriparatide in postmenopausal women
with osteoporosis. [2006]
Denosumab in postmenopausal women with low bone mineral density. [2006]
Once-monthly ibandronate. [2005]
Bisphosphonate therapy improves the outcome of conventional periodontal
treatment: results of a 12-month, randomized, placebo-controlled study. [2005]
Other research related to Binosto (Alendronate)
Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy:
the FLEX study. [2014]
A model of BMD changes after alendronate discontinuation to guide postalendronate
BMD monitoring. [2014]
Endoscopic comparison of alendronate alone and the enteric-coated alendronate
with calcitriol combination in postmenopausal Korean females. [2013]
Effect of early administration of alendronate after surgery for distal radial
fragility fracture on radiological fracture healing time. [2013]
Comparison of alendronate and raloxifene for the management of primary
hyperparathyroidism. [2013]
Alendronate treatment for hip osteoarthritis: prospective randomized 2-year
trial. [2013]
BMD changes and predictors of increased bone loss in postmenopausal women after a
5-year course of alendronate. [2013]
A comparative study of the effects of daily minodronate and weekly alendronate on
upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal
osteoporosis patients. [2013]
Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean
postmenopausal women with early breast cancer receiving aromatase inhibitor: a
double-blind, randomized, placebo-controlled study. [2013]
Effect of low-dose alendronate treatment on bone mineral density and bone
turnover markers in Chinese postmenopausal women with osteopenia and
osteoporosis. [2013]
Efficacy of subgingivally delivered simvastatin in the treatment of patients with
type 2 diabetes and chronic periodontitis: a randomized double-masked controlled
clinical trial. [2013]
Bone loss after heart transplant: effect of alendronate, etidronate, calcitonin,
and calcium plus vitamin D3. [2012]
[Clinical application of alendronate for osteoporosis/osteopenia secondary to
hyperthyroidism]. [Article in Chinese] [2012]
Bone density around endosseous implants in patients taking alendronate: a pilot
study. [2012]
Comparison of clinical efficacy and safety between denosumab and alendronate in
postmenopausal women with osteoporosis: a meta-analysis. [2012]
Alendronate in the prevention of collapse of the femoral head in nontraumatic
osteonecrosis: a two-year multicenter, prospective, randomized, double-blind,
placebo-controlled study. [2012]
Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with
alendronate: a randomized, double-blind, placebo-controlled study. [2012]
Comparative evaluation of isosorbide mononitrate and alendronate in management of
postmenopausal osteoporosis. [2012]
Comparison of alendronate and pamidronate on bone loss in kidney transplant
patients for the first 6 months of transplantation. [2011]
A comparison of the effects of alendronate and alfacalcidol on bone mineral
density around the femoral implant and in the lumbar spine after total hip
arthroplasty. [2011]
Other possibly related research studies
What is the role of hyperbaric oxygen in the management of bisphosphonate-related
osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as
an adjunct to surgery and antibiotics. [2012]
Adherence to bisphosphonate therapy in postmenopausal osteoporotic women. [2011]
Bisphosphonates for osteoporosis in primary biliary cirrhosis. [2011]
Prevention of disuse osteoporosis in rats by Cordyceps sinensis extract. [2012]
Development, reliability, and validity of a new Preference and Satisfaction
Questionnaire. [2011]
Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not
cortical bone in postmenopausal women. [2012]
Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic
viral liver disease. [2011]
Effects of intravenous ibandronate injection on renal function in women with
postmenopausal osteoporosis at high risk for renal disease--the DIVINE study. [2011]
The relative efficacy of nine osteoporosis medications for reducing the rate of
fractures in post-menopausal women. [2011]
Delayed/non-union of upper limb fractures with bisphosphonates: systematic review
and recommendations. [2014]
A Surgeon's guide to advances in the pharmacological management of acute Charcot
neuroarthropathy. [2013]
Comparison of non-vertebral fracture between minodronate and risedronate therapy
in elderly female patients with Alzheimer disease. [2013]
Pure and hybrid causal effects on variables associated with an incident event. [2013]
Interventions for preventing falls in people after stroke. [2013]
Influence of patient perceptions and preferences for osteoporosis medication on
adherence behavior in the Denosumab Adherence Preference Satisfaction study. [2014]
Tooth extraction in osteoporotic patients taking oral bisphosphonates. [2013]
Results of indirect and mixed treatment comparison of fracture efficacy for
osteoporosis treatments: a meta-analysis. [2013]
Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone
mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based
on 9 RCTs. [2014]
Anti-reabsorptive agents in women with osteoporosis: determining statistical
equivalence according to evidence-based methods. [2014]
Time course of bone mineral density changes with denosumab compared with other
drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. [2014]
Bisphosphonates in the management of thalassemia-associated osteoporosis: a
systematic review of randomised controlled trials. [2014]
Change in arterial stiffness associated with monthly bisphosphonate treatment in
women with postmenopausal osteoporosis. [2014]
|